Ventorp F, Bay-Richter C, Nagendra AS, Janelidze S, Matsson VS, Lipton J, Nordstrm U, Westrin , Brundin P, Brundin L (2017) Exendin-4 treatment improves LPS-induced depressive-like behavior without affecting pro-inflammatory cytokines
Peak Wellness versus Hims and Hers Hims and Hers have entered the GLP-1 market aggressively, with some oral formulations advertised as low as $49 to $199 per month
Eliminate Stubborn Pain & Inflammation The combined anti-inflammatory action of both peptides reduces both acute and chronic pain, improving mobility and comfort throughout the body
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly for obesity and type 2 diabetes
Stomach acid separates B12 from dietary proteins, then a protein called intrinsic factor binds to the freed B12 and escorts it to absorption sites in the ileum